|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Final pathologic tumor category (AJCC eighth edition) was 46.9% ypT1, 34.4% ypT2, and 18.7% ypT3.
|
30211728 |
2019 |
|
Rectal Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Pathologic Staging Inconsistency Between ypT4N0 (stage II) and ypT1-2N1 (stage III) After Preoperative Chemoradiotherapy and Total Mesorectal Excision in Rectal Cancer: A Multi-Institutional Study.
|
30595556 |
2019 |
|
aspirin intolerance
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Thus, functional alterations of the RAB1A gene may contribute to aspirin intolerance in asthmatic sufferers.
|
24555545 |
2014 |
|
Ataxia Telangiectasia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
To investigate the relationship between single-nucleotide polymorphisms (SNPs) in the RAB1A gene and aspirin-exacerbated respiratory disease (AERD), asthmatics (n=1197) were categorized into AERD and aspirin-tolerant asthma (ATA).
|
24555545 |
2014 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The high incidence of LNM in the ypT1-2 group needs to be taken into consideration in the context of oncological safety and indicate that LE should be advocated with great caution in this patient subgroup.
|
29929861 |
2018 |
|
Cardiomyopathy, Dilated
|
0.200 |
Biomarker
|
group |
MGD |
|
|
|
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our data suggest that miR-15b-5p induces ERS, apoptosis, and growth inhibition by targeting and suppressing Rab1A, acting as a tumor suppressor gene in HCC.
|
26023735 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression analysis and implication of Rab1A in gastrointestinal relevant tumor.
|
31527621 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these data suggest that miR‑139‑3p plays a tumor suppressive role in breast cancer by targeting RAB1A and may serve as a potential new biomarker for breast cancer prognosis.
|
31485677 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, the oral administration of KPS-A led to substantial inhibition of tumor growth and the expression of proliferating cell nuclear antigen (PCNA), MMP-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), HuR, and Rab1A in the tumor tissues of mice inoculated with YD-10B OSCC cells.
|
22382313 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Rab1a, a member RAS oncogene family, has been reported playing important role in tumor proliferation and migration.
|
29672195 |
2018 |
|
Colorectal Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
RAB1A acts as an oncogene in various cancers, and emerging evidence has verified that RAB1A is an mTORC1 activator in hepatocellular and colorectal cancer, but the role of RAB1A in breast cancer remains unclear.
|
28184936 |
2017 |
|
Colorectal Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Previous studies have reported an oncogenic function of Rab1A in colorectal cancer and hepatocellular carcinomas via the mTOR pathway.
|
31527621 |
2019 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Thus, our findings indicate that Rab1A plays an important role in CRC and may provide a therapeutic target for CRC, particularly for mTORC1‑targeted therapy‑resistant cancers.
|
30896866 |
2019 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Emerging evidence has verified that Rab1A plays an oncogenic role in several human malignancies including breast cancer, lung cancer, and hepatocellular carcinomas.
|
30058685 |
2018 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Taken together, MNX1-AS1 functions as a sponge to miR-218-5p to modulate RAB1A expression in bladder cancer, which suggests that MNX1-AS1 might serve as a novel therapeutic target and a novel biomarker for metastasis and prognosis in bladder cancer.
|
31843814 |
2020 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Patients with rectal cancer staged ypT4N0 were associated with higher locoregional recurrence and distant metastasis rates than those staged ypT1-2N1 in the current staging system.
|
30595556 |
2019 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
miR-634 exhibits anti-tumor activities toward hepatocellular carcinoma via Rab1A and DHX33.
|
27693040 |
2016 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Taken together, our data suggest that miR-15b-5p induces ERS, apoptosis, and growth inhibition by targeting and suppressing Rab1A, acting as a tumor suppressor gene in HCC.
|
26023735 |
2015 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
MiR-223 modulates hepatocellular carcinoma cell proliferation through promoting apoptosis via the Rab1-mediated mTOR activation.
|
27998765 |
2017 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Previous studies have reported an oncogenic function of Rab1A in colorectal cancer and hepatocellular carcinomas via the mTOR pathway.
|
31527621 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.040 |
Biomarker
|
disease |
BEFREE |
Previous studies have reported an oncogenic function of Rab1A in colorectal cancer and hepatocellular carcinomas via the mTOR pathway.
|
31527621 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.040 |
Biomarker
|
disease |
BEFREE |
Rab1A promotes proliferation and migration abilities via regulation of the HER2/AKT-independent mTOR/S6K1 pathway in colorectal cancer.
|
30896866 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.040 |
Biomarker
|
disease |
BEFREE |
RAB1A acts as an oncogene in various cancers, and emerging evidence has verified that RAB1A is an mTORC1 activator in hepatocellular and colorectal cancer, but the role of RAB1A in breast cancer remains unclear.
|
28184936 |
2017 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Taken together, these data suggest that miR‑139‑3p plays a tumor suppressive role in breast cancer by targeting RAB1A and may serve as a potential new biomarker for breast cancer prognosis.
|
31485677 |
2019 |